A5080928437- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Lymphoma Diagnosis and Treatment
- Family Support in Illness
- Chemotherapy-induced cardiotoxicity and mitigation
- Autoimmune and Inflammatory Disorders
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Calcium signaling and nucleotide metabolism
- Biomedical Ethics and Regulation
- Immunodeficiency and Autoimmune Disorders
- Adolescent and Pediatric Healthcare
- Infant Development and Preterm Care
- Respiratory Support and Mechanisms
- Assisted Reproductive Technology and Twin Pregnancy
- Cerebral Palsy and Movement Disorders
- Inflammatory Bowel Disease
- T-cell and Retrovirus Studies
- Cardiac Arrest and Resuscitation
- Chemotherapy-induced organ toxicity mitigation
- Neonatal Respiratory Health Research
- Neuroscience of respiration and sleep
- PI3K/AKT/mTOR signaling in cancer
- Microscopic Colitis
Semmelweis University
2017-2024
Abstract In the pathogenesis of chronic lymphocytic leukemia (CLL) microenvironment plays an important role, as it produces survival signals and mediates drug resistance. Lenalidomide, which has immunomodulatory effect, can enhance activation T‐, NK‐cells endothelial cells, however there are no data available whether modulate bone marrow stromal cells (BMSCs). our study, we investigated effects lenalidomide on BMSCs CLL cells. were cultured alone or with treated lenalidomide. Apoptosis,...
Introduction: Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature CD5+ CD23+ B cells in peripheral blood, bone marrow and secondary lymphatic tissues. It well known that progression CLL highly dependent on tumor microenvironment. Lenalidomide (Celgene) an immunomodulatory drug with significant therapeutic activity CLL. In this study, we investigated how lenalidomide influence viability surface molecule expression, especially markers involved costimulation,...